CAMBRIDGE, Mass., Aug. 25, 2022 -- Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced...
Cerexa expands portfolio of novel anti-infective therapies through in-licensing agreement with Meiji Seika Kaisha
News | 11. 01. 2006
Cerexa
Cerexa Inc. today announced it has expanded its portfolio of novel anti-infective therapies through an in-licensing agreement with Meiji Seika Kaisha Ltd.
